Unilever says GSK consumer arm ‘strong strategic fit’ for business
In this article (5)
Dove soap maker Unilever signaled on Monday it would pursue a deal for GlaxoSmithKline’s consumer health business, calling it a “strong strategic fit” after its 50-billion-pound approach ($68.4 billion) was rejected.
The update comes after GSK confirmed over the weekend that it had rejected the Unilever offer for its consumer healthcare business, which is home to brands such as Sensodyne toothpaste and Emergen-C vitamin supplement.
“The acquisition would create scale and a growth platform for the combined portfolio in the U.S., China and India, with further opportunities in other emerging markets,” Unilever said, pointing to synergies in the oral care and vitamin supplements business.
Unilever held talks with banks about additional financing for a potential sweetened offer for GSK’s consumer products division, Bloomberg News reported on Sunday, citing people familiar with the matter.
Unilever, which is set to announce an initiative later this month to strengthen its business, said on Monday it was committed to “strict financial discipline” for any acquisitions.
Questions & Answers
Q.What is Unilever's stated reason for wanting to acquire GSK's consumer health business?
What is Unilever's stated reason for wanting to acquire GSK's consumer health business?
Unilever believes the acquisition would create scale and a growth platform in the U.S., China, and India, with further opportunities in other emerging markets. They also noted synergies in oral care and vitamin supplements.
Q.Which specific GSK brands were mentioned in the context of this acquisition attempt?
Which specific GSK brands were mentioned in the context of this acquisition attempt?
The article mentions GSK's consumer healthcare business is home to brands such as Sensodyne toothpaste and Emergen-C vitamin supplement.
Q.Has Unilever indicated they might make another offer for the GSK consumer health business?
Has Unilever indicated they might make another offer for the GSK consumer health business?
Yes, Unilever reportedly held talks with banks about additional financing for a potential sweetened offer for GSK's consumer products division.
Q.What was the value of Unilever's initial offer for GSK's consumer health business?
What was the value of Unilever's initial offer for GSK's consumer health business?
Unilever's initial approach for GlaxoSmithKline’s consumer health business was valued at 50 billion pounds, which is equivalent to $68.4 billion.
Reader pulse
Is Unilever's pursuit of GSK consumer health a good strategy?
24,270 votes so far